Pratteln, Switzerland, September 14, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that Emory University scientists and partner ReveraGen Biopharma Inc. have published new data on the molecular mode of action of […]
Pratteln, Switzerland, September 11, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed enrollment into the pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular […]
• License gives Santhera worldwide rights to vamorolone, now also including the major marketsJapan and South Korea, and paves the way for partnering in additional indications• Agreements with Idorsia and […]
— FDA grants Priority Review Status and sets regulatory action date for February 25, 2021 —— FDA has indicated it does not currently plan to hold an advisory committee meeting […]
CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]
CureDuchenne is thrilled to relay the news that NS Pharma has received FDA marketing authorization for Vitolarsen, an exon 53 skipping therapy. The entire Duchenne community is grateful for NS […]
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has […]
This month’s Catabasis Connection:
NS Pharma Announces Launch of Patient Support HubPARAMUS, NJ: July 7, 2020 – NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. […]
